In the past week, CRVS stock has gone down by -9.93%, with a monthly decline of -28.42% and a quarterly plunge of -33.66%. The volatility ratio for the week is 8.99%, and the volatility levels for the last 30 days are 8.39% for Corvus Pharmaceuticals Inc The simple moving average for the past 20 days is -20.75% for CRVS’s stock, with a -27.43% simple moving average for the past 200 days.
Is It Worth Investing in Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Right Now?
Moreover, the 36-month beta value for CRVS is 1.06. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CRVS is 36.90M and currently, short sellers hold a 3.79% of that float. On April 18, 2024, CRVS’s average trading volume was 198.91K shares.
CRVS) stock’s latest price update
The stock price of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has dropped by -7.48 compared to previous close of 1.47. Despite this, the company has seen a fall of -9.93% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-17 that The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Analysts’ Opinion of CRVS
Many brokerage firms have already submitted their reports for CRVS stocks, with Oppenheimer repeating the rating for CRVS by listing it as a “Outperform.” The predicted price for CRVS in the upcoming period, according to Oppenheimer is $7 based on the research report published on August 18, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see CRVS reach a price target of $8. The rating they have provided for CRVS stocks is “Buy” according to the report published on December 01st, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to CRVS, setting the target price at $10 in the report published on May 27th of the previous year.
CRVS Trading at -31.46% from the 50-Day Moving Average
After a stumble in the market that brought CRVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.54% of loss for the given period.
Volatility was left at 8.39%, however, over the last 30 days, the volatility rate increased by 8.99%, as shares sank -30.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.34% lower at present.
During the last 5 trading sessions, CRVS fell by -9.93%, which changed the moving average for the period of 200-days by -40.61% in comparison to the 20-day moving average, which settled at $1.6860. In addition, Corvus Pharmaceuticals Inc saw -22.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRVS starting from Grais Linda, who purchase 10,000 shares at the price of $2.45 back on May 15 ’23. After this action, Grais Linda now owns 10,000 shares of Corvus Pharmaceuticals Inc, valued at $24,500 using the latest closing price.
Stock Fundamentals for CRVS
The total capital return value is set at -0.61. Equity return is now at value -57.02, with -47.51 for asset returns.
Based on Corvus Pharmaceuticals Inc (CRVS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -17.42. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -19.44.
Currently, EBITDA for the company is -23.26 million with net debt to EBITDA at 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.
Conclusion
To wrap up, the performance of Corvus Pharmaceuticals Inc (CRVS) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
